- Home
- KRON vs LVTX Comparison
KRON vs LVTX Comparison
Compare KRON & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- LVTX
- Stock Information
- Founded
- KRON 2017
- LVTX 2016
- Country
- KRON United States
- LVTX Netherlands
- Employees
- KRON N/A
- LVTX N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- KRON Health Care
- LVTX Health Care
- Exchange
- KRON Nasdaq
- LVTX Nasdaq
- Market Cap
- KRON 60.3M
- LVTX 43.9M
- IPO Year
- KRON 2020
- LVTX 2021
- Fundamental
- Price
- KRON $0.93
- LVTX $1.65
- Analyst Decision
- KRON Strong Buy
- LVTX Strong Buy
- Analyst Count
- KRON 2
- LVTX 2
- Target Price
- KRON $4.13
- LVTX $6.00
- AVG Volume (30 Days)
- KRON 59.4K
- LVTX 31.7K
- Earning Date
- KRON 11-11-2024
- LVTX 11-14-2024
- Dividend Yield
- KRON N/A
- LVTX N/A
- EPS Growth
- KRON N/A
- LVTX N/A
- EPS
- KRON N/A
- LVTX N/A
- Revenue
- KRON $8,412,000.00
- LVTX $7,398,000.00
- Revenue This Year
- KRON $52.58
- LVTX N/A
- Revenue Next Year
- KRON N/A
- LVTX N/A
- P/E Ratio
- KRON N/A
- LVTX N/A
- Revenue Growth
- KRON 172.76
- LVTX N/A
- 52 Week Low
- KRON $0.69
- LVTX $1.13
- 52 Week High
- KRON $1.60
- LVTX $6.47
- Technical
- Relative Strength Index (RSI)
- KRON 44.01
- LVTX 47.75
- Support Level
- KRON $0.85
- LVTX $1.56
- Resistance Level
- KRON $0.97
- LVTX $1.75
- Average True Range (ATR)
- KRON 0.06
- LVTX 0.07
- MACD
- KRON -0.00
- LVTX 0.00
- Stochastic Oscillator
- KRON 43.82
- LVTX 47.37
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.